2 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Albinism: new trials by email Literature Review of Albinism trials Research Report on Albinism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST Imatinib Mesylate, Local resection - Gastrointestinal Stromal Tumor of Rectum | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 23 | 2023-10-01 | 2023-08-01 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism VITICELL, PLACEBO - Vitiligo, Piebaldism | Phase 3 | Completed | Laboratoires Genévrier | 38 | 2014-04-29 | 2019-10-14 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Completed | AB Science | 135 | 2008-12-01 | 2019-12-03 |
| T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Stem Cell Transplant, Myeloablative conditioning regimen - Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 22 | 2000-09-01 | 2018-01-23 |
Piebaldism (4) · Blushing (2) · Mastocytosis (2) · Mastocytosis, Systemic (2) · Pruritus (2) · Chediak-Higashi Syndrome (1) · Gastrointestinal Stromal Tumors (1) · Hematologic Diseases (1) · Histiocytosis, Langerhans-Cell (1) · Immune System Diseases (1) · Lymphohistiocytosis, Hemophagocytic (1) · Lymphoproliferative Disorders (1) · Vitiligo (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Eye Diseases, Hereditary (5) · Genetic Diseases, Inborn (5) · Amino Acid Metabolism, Inborn Errors (4) · Hypopigmentation (4) · Metabolic Diseases (4) · Metabolism, Inborn Errors (4) · Nutritional and Metabolic Diseases (4) · Pigmentation Disorders (4) · Skin Diseases (4) · Skin Diseases, Genetic (4) · Skin and Connective Tissue Diseases (4) · Neoplasms (3) · Neoplasms by Histologic Type (3)
masitinib (2) · Busulfan (1) · Cyclophosphamide (1) · Imatinib Mesylate (1) · Mastectomy, Segmental (1) · Stem Cell Transplantation (1)
AB Science (2) · Fujian Medical University Union Hospital (1) · Laboratoires Genévrier (1) · Masonic Cancer Center, University of Minnesota (1)
France (3) · United States (2) · Belgium (1) · China (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1) · Ukraine (1) · United Kingdom (1)
Angela Smith, MD (1) · Cristina Bulai Livideanu, MD, MSc (1) · Nanja Van Geel, Pr (1) · Olivier Lortholary, MD, PhD (1) · Weizhong Jiang, MD (1)
2016 (1)